Quantum Genomics Quantum Genomics
  • Company
    • Management
    • Board of directors
    • Inventors
    • Scientific and clinical advisory board
  • Investors
    • Press releases
    • Financial documents
      • Annual information
      • Semi-annual information
      • Other regulated informations
    • Shareholder letter
    • General meetings
    • Shareholding
    • Financial calendar
    • Contacts
  • Contact us
  • Français
Actualités

Quantum Genomics Reports First Half 2020 Financial Results

Quantum on 1 October 2020

Quantum Genomics Reports First Half 2020 Financial Results and Provides Corporate Update

Read the press realease (french only)

Previous Post (p) Quantum Genomics to give an exclusive license for firibastat in South-East Asia, Australia and New Zealand
Next Post (n) Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Qilu Pharmaceutical
Quantum 2020-10-01T18:51:01+02:00
About

Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.

Contact us

33 rue Marbeuf
75008 Paris

[email protected]
+33(0)1 85 34 77 70

Write us

Quick access
  • Scientific Publications
Search

 

© 2019 Quantum Genomics - Legal notice - Website terms and conditions

  • Company
    • Management
    • Board of directors
    • Inventors
    • Scientific and clinical advisory board
  • Investors
    • Press releases
    • Financial documents
      • Annual information
      • Semi-annual information
      • Other regulated informations
    • Shareholder letter
    • General meetings
    • Shareholding
    • Financial calendar
    • Contacts
  • Contact us
  • Français
  • Blog
  • Home
  • Contact us